Brain stimulation for depression: the research on rTMS, tDCS, VNS and PBM compared
Four neuromodulation approaches to depression have their own DeepSynaps evidence map: rTMS for major depressive disorder, tDCS for depression, VNS for treatment-resistant depression, PBM for major depressive disorder. This article compares how much research exists for each: papers, randomised trials, reviews and growth over time (snapshot 2026-09-25).
Papers, trials and reviews
| Treatment and condition | Papers | RCTs | Meta-analyses | Systematic reviews | RCT share |
|---|---|---|---|---|---|
| rTMS for major depressive disorder | 3,320 | 713 | 272 | 141 | 21.5% |
| tDCS for depression | 1,232 | 344 | 113 | 84 | 27.9% |
| VNS for treatment-resistant depression | 1,043 | 91 | 24 | 32 | 8.7% |
| PBM for major depressive disorder | 129 | 27 | 2 | 5 | 20.9% |
RCT share is the proportion of a map's papers labelled as randomised controlled trials.
How the research has grown
- rTMS for major depressive disorder: 694 papers in 2016–2020, 1,533 in 2021–2025
- tDCS for depression: 336 papers in 2016–2020, 599 in 2021–2025
- VNS for treatment-resistant depression: 176 papers in 2016–2020, 437 in 2021–2025
- PBM for major depressive disorder: 13 papers in 2016–2020, 96 in 2021–2025
The most-cited trial on each map
- rTMS: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Blumberger et al., 2018. 897 citations.
- tDCS: The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. Brunoni et al., 2013. 416 citations.
- VNS: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Rush et al., 2005. 370 citations.
- PBM: Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder: The ELATED-3 Multicenter, Randomized, Sham-Controlled Trial. Iosifescu et al., 2022. 18 citations.
Citation counts measure attention in the literature, not the size or quality of an effect.
How to read these numbers
Each map counts papers tagged to that treatment and condition in the curated DeepSynaps v6 corpus; papers Jev confidently judged off-topic are excluded. Counts describe how much has been published, not how well the treatment works.
Study designs are AI-classified by Jev: advisory, not clinician-reviewed. Some papers on each map have no confident study-design label yet, so the trial and review columns are lower bounds.
Totals include papers from 2026, which was still in progress at the snapshot (2026-09-25). The growth comparison uses complete years only.
Decision support only. This article summarises published literature; it is not medical advice or a recommendation for any patient. Data snapshot 2026-09-25.